Stockscreener 앱 받기
78.04
4.12%
3.11
전일 마감가:
$74.93
열려 있는:
$75.21
하루 거래량:
704.13K
Relative Volume:
0.28
시가총액:
$10.93B
수익:
$1.09B
순이익/손실:
$233.57M
주가수익비율:
50.73
EPS:
1.5382
순현금흐름:
$327.01M
1주 성능:
+10.62%
1개월 성능:
+27.65%
6개월 성능:
+97.02%
1년 성능:
+496.48%
1일 변동 폭
$74.45
$78.28
1주일 범위
$69.15
$78.28
52주 변동 폭
$12.44
$78.28
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
명칭
Arrowhead Pharmaceuticals Inc
전화
626-696-4702
주소
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
78.04 | 10.49B | 1.09B | 233.57M | 327.01M | 1.5382 |
VRTX
Vertex Pharmaceuticals Inc
|
426.84 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
722.04 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.63 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.09 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-21 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | 개시 | Goldman | Neutral |
| 2023-12-04 | 개시 | BofA Securities | Buy |
| 2023-09-19 | 개시 | Citigroup | Neutral |
| 2023-07-21 | 개시 | TD Cowen | Outperform |
| 2023-05-12 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-12 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | 재개 | Goldman | Buy |
| 2021-08-06 | 재확인 | Chardan Capital Markets | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-21 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | 개시 | UBS | Buy |
| 2020-11-19 | 개시 | Citigroup | Buy |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-05-08 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-04-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | 개시 | Goldman | Neutral |
| 2020-01-21 | 개시 | SVB Leerink | Underperform |
| 2019-12-13 | 개시 | Oppenheimer | Perform |
| 2019-11-29 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-27 | 재확인 | B. Riley FBR | Buy |
| 2019-11-25 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | 재확인 | Chardan Capital Markets | Buy |
| 2019-10-03 | 개시 | Robert W. Baird | Outperform |
| 2018-09-07 | 업그레이드 | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | 재확인 | Chardan Capital Markets | Buy |
| 2018-08-08 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-07-02 | 재확인 | Chardan Capital Markets | Buy |
모두보기
Arrowhead Pharmaceuticals Inc 주식(ARWR)의 최신 뉴스
Arrowhead and Madrigal sign global licence for MASH RNAi therapy - Yahoo Finance
Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset - Pharmaceutical Technology
ViaSat, Arrowhead Pharmaceuticals, and Sphere Entertainment Lead Stock Returns - Markets Mojo
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals - Arrowhead Pharmaceuticals, Inc.
Madrigal expands MASH pipeline in potential $1B Arrowhead deal - BioWorld News
Arrowhead Pharmaceuticals stock hits 52-week high at 77.23 USD - Investing.com
Madrigal picks up another siRNA asset for MASH, betting up to $1B with Arrowhead - BioSpace
Biotechnology company Arrowhead Pharmaceuticals announces a major collaboration agreement with Madrigal Pharmaceuticals. - Bitget
Arrowhead licenses MASH drug candidate to Madrigal for $1B By Investing.com - Investing.com Canada
JPMorgan Expects Arrowhead Pharma Stock to Rally on RNAi Portfolio Growth - TIKR.com
MSN Money - MSN
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events - Business Wire
The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Australian Approval Of REDEMPLO For FCS - Yahoo Finance
Arrowhead upgraded at Morgan Stanley on upcoming catalysts - MSN
Is Arrowhead Pharmaceuticals (ARWR) Stock Price Out Of Line With Recent 1-Year Surge? - Sahm
Kornitzer Capital Management Inc. KS Makes New $2.38 Million Investment in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead (ARWR) Rated Buy on Metabolic Pipeline Potential - Insider Monkey
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Vanguard Group Inc. - MarketBeat
ARWR Initiates Coverage By JP Morgan -- Rating Set to Overweight - GuruFocus
ARWR SEC FilingsArrowhead Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Now Covered by JPMorgan Chase & Co. - MarketBeat
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS) - Arrowhead Pharmaceuticals, Inc.
J.P. Morgan Initiates Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Announces Target Price $88 - Moomoo
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
JPMorgan initiates Arrowhead Pharma stock coverage with overweight rating - Investing.com
JP Morgan Initiates Coverage of Arrowhead Pharmaceuticals (ARWR) with Overweight Recommendation - MSN
Arrowhead Pharmaceuticals | SCHEDULE 13G: Others - Moomoo
5 Most Profitable Biotech Stocks to Buy Now - Insider Monkey
Complement Inhibitors Market Outlook Remains Strong During the Forecast Period (2026–2036) with Increasing Adoption of C5 and C3 Targeted Drugs | DelveInsight - GlobeNewswire Inc.
Behavioral Patterns of ARWR and Institutional Flows - Stock Traders Daily
Arrowhead Pharmaceuticals (ARWR) Projected to Post Earnings on Thursday - MarketBeat
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Vanguard reports 5.05% stake in Arrowhead Pharmaceuticals (ARWR) - Stock Titan
Arrowhead Pharmaceuticals, Inc. $ARWR Shares Acquired by Pictet Asset Management Holding SA - MarketBeat
Vanguard Portfolio Management (NASDAQ: ARWR) reports 5.19% stake in Arrowhead - Stock Titan
FengHe Fund Management Pte. Ltd. Makes New $17.71 Million Investment in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Arrowhead rises as FDA approves lead drug for rare disorder - msn.com
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome in Europe - marketscreener.com
Sarepta sells Arrowhead stock, activates $100M milestone payment - MSN
Arrowhead Pharmaceuticals (ARWR) price target increased by 23.01% to 77.60 - MSN
Insider Sell: James Hamilton Sells 10,000 Shares of Arrowhead Ph - GuruFocus
Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Insider Sells 10,000 Shares of Stock - MarketBeat
Arrowhead (NASDAQ: ARWR) CMO sells 10,000 pre-planned shares - Stock Titan
Arrowhead CFO Daniel Apel sells $934,285 in company stock By Investing.com - Investing.com Australia
Arrowhead Pharmaceuticals CMO James Hamilton sells $750,000 in stock By Investing.com - Investing.com Australia
Arrowhead Pharmaceuticals CMO James Hamilton sells $750,000 in stock - Investing.com UK
Arrowhead CFO Daniel Apel sells $934,285 in company stock - Investing.com
Arrowhead (ARWR) CFO Apel sells 13,095 shares in Rule 10b5-1 trades - Stock Titan
BlackRock holds 12.2% of Arrowhead Pharmaceuticals (NASDAQ: ARWR) in 13G/A - Stock Titan
Sanofi, Arrowhead, Novartis win CHMP backing (SNY:NASDAQ) - Seeking Alpha
Arrowhead (ARWR) Secures Positive EMA Opinion for REDEMPLO in FC - GuruFocus
Arrowhead Pharmaceuticals Inc (ARWR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Arrowhead Pharmaceuticals Inc 주식 (ARWR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hamilton James C | Chief Medical Officer |
Apr 23 '26 |
Sale |
75.00 |
10,000 |
750,000 |
226,958 |
0.78%
3.01%
자본화:
|
볼륨(24시간):